Category: Health Science
-
![Valeo Pharma(VPH), complicated sector but simple business model]()
Valeo Pharma(VPH), complicated sector but simple business model
Stock Performance From the chart below it seemed like the Valeo Pharma (“VPH”) shareholders have had quite a wild ride over the last few years. Starting in 2019 the stock was trading at $0.72 per share, but by mid-August, the stock had dropped by almost 50% to around $0.30 per share before it did nothing…
-
![Valeo Pharma (VPH.C) CEO Steve Saviuk talks specialty pharma opportunity (Ep4) Chris’ Corner]()
Valeo Pharma (VPH.C) CEO Steve Saviuk talks specialty pharma opportunity (Ep4) Chris’ Corner
Steve Saviuk, president and CEO of Valeo Pharma (VPH.C), talks about the transformative partnerships with international players such as Novartis and members of the Canadian Healthcare Industry, that allow the company to bring leading innovative products to the Canadian market. Tune in!
-
![Undervalued Valeo Pharma (VPH.C) and their asthma inhalers may be 2021’s shiniest hidden gem]()
Undervalued Valeo Pharma (VPH.C) and their asthma inhalers may be 2021’s shiniest hidden gem
There’s nothing more terrifying than watching a loved one pause, clutch their throat and start gasping for air. The first time it happens provokes the mad scramble, as she points at her purse and mimes the universal L-shaped hand pattern for an asthma inhaler. She sits while you go digging through spent candy wrappers, old…
-
![Idea for the future: Eastower (OVO.P.V) will be a 5G wireless ‘picks and shovels’ play]()
Idea for the future: Eastower (OVO.P.V) will be a 5G wireless ‘picks and shovels’ play
“What sector is hot?” is the one question I get asked more than any other. Well, okay, maybe “Why didn’t you respond to my text?” is the most asked, but the sector question is a close second. The answer can change by the month. We’ve had cannabis runs, crypto runs, psychedelic runs, mining runs, e-sports…
-
![Gavinchuk: I’m not seeing enough nerdy data talk within the psychedelics space]()
Gavinchuk: I’m not seeing enough nerdy data talk within the psychedelics space
Forget weed crypto First off, most all of those crypto/cannabis hybrid deals were super cringe, and I never saw the point of combining the two, at least not at the scale at which it happened. But psychedelics is a different beast, and tech integrations make a lot more sense than they did with cannabis. It…
-
![Cybin (CYBN.N) finishes its first trading day on the NYSE]()
Cybin (CYBN.N) finishes its first trading day on the NYSE
The NYSE Cybin (CYBN.N) just finished its first trading day on the New York Stock Exchange (NYSE) after announcing the upcoming uplisting last month. It was a less than desirable day for the stock, but it’s really only a blip when factoring in the runup to the NYSE debut. In recent months we have seen…
-
![Cybin (CYBN.NE) Closes Overnight Public Offering, Fortifies Cash Balance]()
Cybin (CYBN.NE) Closes Overnight Public Offering, Fortifies Cash Balance
Cybin (CYBN.NE) announced today that it has closed its previously announced overnight marketed offering including the exercise in full of the over-allotment option granted to the Underwriters. “Investor demand for this financing was very strong and we are thankful for the outstanding work of our banking syndicate partners and advisors and we welcome all new…
-
![Filament Health (FH.NE) is experimenting with mushrooms and compounds far beyond just psilocybin]()
Filament Health (FH.NE) is experimenting with mushrooms and compounds far beyond just psilocybin
Mushroom enthusiasts Filament Health (FH.NE) is looking at mushroom compounds far beyond just psilocybin as the company is run by actual mushroom enthusiasts with access to a lot of tools. Filament has the capabilities to experiment and come up with interesting new compounds, extraction methods, and potential future products that probably go far beyond whatever…
-
![Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering]()
Cybin (CYBN.NE) gets final approval to list on NYSE American and announces public offering
Cybin (CYBN.NE) announced that they have received final approval from the New York Stock Exchange (NYSE) to list its shares on the NYSE American exchange. Beginning next Thursday, on August 5, 2021, Cybin will begin trading on the NYSE American under the ticker “CYBN”. Cybin will continue to trade on the NEO exchange, also under…
-
![Xphyto (XPHY.C) partner/acquisition target achieves major milestone with Covid-19 biosensor candidates]()
Xphyto (XPHY.C) partner/acquisition target achieves major milestone with Covid-19 biosensor candidates
On July 28, 2021 Xphyto Therapeutics (XPHY.C) announced that its acquisition target, 3a-diagnostics GmbH, has identified the first saliva-activated in-mouth biosensor candidates for the detection of a COVID-19 infection. Xphyto Therapeutics is a bioscience accelerator focused on next-generation drug delivery, diagnostic and new active pharmaceutical ingredient investment opportunities. 3a-diagnostics is currently a commercial partner of…
